Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (LLY)
NYSE:LLY
Holding LLY?
Track your performance easily
LLY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$516.57 - $972.53
Previous Close$921.49
Volume9.92M
Average Volume (3M)3.27M
Market Cap
$875.81B
Enterprise Value$901.41B
Total Cash (Recent Filing)$3.36B
Total Debt (Recent Filing)$28.89B
Price to Earnings (P/E)115.1
Beta0.43
Next Earnings
Oct 30, 2024EPS Estimate
$4.49Last Dividend Ex-Date
Aug 15, 2024Dividend Yield0.55%
Share Statistics
EPS (TTM)8.01
Shares Outstanding950,425,778
10 Day Avg. Volume2,969,756
30 Day Avg. Volume3,265,200
Standard Deviation0.09
R-Squared0.06
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)64.58
Price to Sales (P/S)22.34
Price to Cash Flow (P/CF)148.30
P/FCF Ratio900.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue23.16
Enterprise Value/Gross Profit33.33
Enterprise Value/Ebitda83.27
Forecast
1Y Price Target
$1,049.18Price Target Upside13.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Eli Lilly & Co News
Bulls Say, Bears Say
Bulls Say
EarningsAnalyst resumes coverage with a Buy rating and a price target of $1,060 per share, driven by increased tirzepatide forecasts based on latest reported sales, script trends, and guidance.
Market StrategySingle-use vial doses improve on significant manufacturing constraints for autoinjectors, expanding patient access to Zepbound through the Lilly Direct self-pay channels.
Pipeline UpdatesNotable pipeline updates for LLY include adding a second oral GLP-1R non-peptide agonist and initiating Phase 1 for next-gen monthly GIP/GLP-1 dual agonist molecule.
Bears Say
CompetitionCompetition is looming with companies like ZEAL, VKTX, GPCR, and Roche posing potential threats.
Regulatory ChallengesEMA's CHMP adopted a negative opinion for Leqembi and recommended the EC to not grant marketing authorization in the EU.
Supply IssuesSeveral of LLY's GLP-1 products went under supply shortage.
---
Ownership Overview
10.90% Insiders
24.54% Mutual Funds
43.98% Other Institutional Investors
20.57% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LLY FAQ
What was Eli Lilly & Co’s price range in the past 12 months?
Eli Lilly & Co lowest stock price was $516.57 and its highest was $972.53 in the past 12 months.
What is Eli Lilly & Co’s market cap?
Currently, no data Available
When is Eli Lilly & Co’s upcoming earnings report date?
Eli Lilly & Co’s upcoming earnings report date is Oct 30, 2024 which is in 38 days.
How were Eli Lilly & Co’s earnings last quarter?
Eli Lilly & Co released its earnings results on Aug 08, 2024. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.743 by $1.177.
Is Eli Lilly & Co overvalued?
According to Wall Street analysts Eli Lilly & Co’s price is currently Undervalued.
Does Eli Lilly & Co pay dividends?
Eli Lilly & Co pays a Quarterly dividend of $1.3 which represents an annual dividend yield of 0.55%. See more information on Eli Lilly & Co dividends here
What is Eli Lilly & Co’s EPS estimate?
Eli Lilly & Co’s EPS estimate is $4.49.
How many shares outstanding does Eli Lilly & Co have?
Eli Lilly & Co has 950,425,800 shares outstanding.
What happened to Eli Lilly & Co’s price movement after its last earnings report?
Eli Lilly & Co reported an EPS of $3.92 in its last earnings report, beating expectations of $2.743. Following the earnings report the stock price went up 9.477%.
Which hedge fund is a major shareholder of Eli Lilly & Co?
Among the largest hedge funds holding Eli Lilly & Co’s share is PRIMECAP Management Co. It holds Eli Lilly & Co’s shares valued at 18B.
---
Eli Lilly & Co Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,049.18 (13.86% Upside)
$1,049.18 (13.86% Upside)
Blogger Sentiment
Bullish
LLY Sentiment 82%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $576.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.85%
12-Months-Change
Fundamentals
Return on Equity
59.63%
Trailing 12-Months
Asset Growth
31.12%
Trailing 12-Months
Company Description
Eli Lilly & Co
Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is headquartered in Indianapolis, Indiana.
---
LLY Company Deck
---
LLY Earnings Call
Q2 2024
0:00 / 0:00
---
LLY Revenue Breakdown
84.44% Net product revenue
15.56% Collaboration and other revenue
---
LLY Stock 12 Month Forecast
Average Price Target
$1,049.18
▲(13.86% Upside)
Technical Analysis
Best Analysts Covering LLY
1 Year
1 Year Success Rate
29/29 ratings generated profit
1 Year Average Return
+58.22%
reiterated a buy rating 26 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +58.22% per trade.
---